Nenocorilant features among the latest industry projects newly into phase 1.
ApexOnco Front Page
Recent articles
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
After promising early data in head and neck, J&J plans a new phase 3, Origami-5.
The first TUB-040 data come just after Tubulis raised €308m.
The battle intensifies as LY4170156 matches torvuta-S with activity in FRα <25% expresers.
But the ESMO discussant recommends against widespread use in hormone-sensitive disease.
Both are heralded as a new first-line standard of care, but Datroway seems to have the edge.
Artios, Synnovation and Novartis show mere glimmers of activity.
